From: Debbie Blough <email@example.com>
Date: Wed, Dec 12, 2018 at 2:29 PM
Subject: FW: Announcing Drug Design Lecture Series with Nicholas Meanwell
To: firstname.lastname@example.org. <email@example.com>
Announcing a new lecture series titled Topics in Drug Design, hosted by Nicholas A. Meanwell, Ph.D. Beginning January 8 and running through 2019, Dr. Meanwell will deliver 6 lectures on drug design. Lectures are from 4 – 5 PM, and will be in Room 100 at the PA Biotechnology Center, 3805 Old Easton Road, Doylestown, PA 18902. Please join us – and feel free to forward this announcement to your colleagues!
Dr. Meanwell has a Ph.D. from the University of Sheffield and completed a Postdoctoral Fellowship at Wayne State University. He joined Bristol-Myers Squibb in 1982 and has led the antiviral chemistry group since 1992. They have pioneered several mechanistically novel antiviral approaches including influenza and respiratory syncytial virus fusion inhibitors, HIV-1 attachment inhibitors and HCV NS5A inhibitors. They have also completed Phase 3 clinical trials of a combination of the HCV NS5A inhibitor daclatasvir and the HCV NS3 inhibitor asunaprevir.